Abstract
ATP10B mutations have been described in patients with Parkinson’s disease and dementia with Lewy body disease, and we previously established ATP10B as a late endo-/lysosomal lipid flippase transporting both phosphatidylcholine (PC) and glucosylceramide (GluCer) from the lysosomal exoplasmic to cytoplasmic membrane leaflet. Since other lipid flippases regulate cellular lipid uptake, we examined here whether ATP10B impacts cellular lipid uptake. Transient co-expression of ATP10B with its obligatory subunit CDC50A stimulated the uptake of fluorescently (NBD-) labeled PC in HeLa cells. This uptake is dependent on the transport function of ATP10B, is impaired by disease-associated mutations and appears specific for NBD-PC. Uptake of non-ATP10B substrates, such as NBD-sphingomyelin, NBD-phosphatidylethanolamine or NBD-lyso-PC is not increased. Remarkably, in stable cell lines co-expressing ATP10B/CDC50A we only observed increased NBD-PC uptake following treatment with rotenone, a mitochondrial complex I inhibitor that induces transport-dependent ATP10B phenotypes. Conversely, Im95m and WM-115 cells with endogenous ATP10B expression, present a decreased NBD-PC uptake following ATP10B knockdown, an effect that is exacerbated under rotenone stress. Our data show that the endo-/lysosomal lipid flippase ATP10B contributes to cellular PC uptake under specific cell stress conditions.
Competing Interest Statement
The authors have declared no competing interest.
Abbreviations
- BSA
- bovine serum albumin
- FBS
- fetal bovine serum
- GalCer
- galactosylceramide
- Gcase
- glucocerebrosidase
- GluCer
- glucosylceramide
- HBSS
- Hanks balanced sodium solution
- HexCer
- hexosylceramide
- KD
- knockdown
- NEEA
- non essential amino acids
- NBD
- nitrobenzoxadiazole
- PBS
- phohsphate buffered saline
- PC
- phosphatidylcholine
- PD
- Parkinson’s disease
- PE
- phosphatidylethanolamine
- PM
- plasma membrane
- PS
- phosphatidylserine
- SM
- sphingomyelin
- WT
- wild type